N-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-(t-butyldimethylsilyloxy)-6-phenyl-2(R)-(phenylmethyl)hexanoic acid | 98818-51-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: N-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-(t-butyldimethylsilyloxy)-6-phenyl-2(R)-(phenylmethyl)hexanoic acid
• 英文别名: (2R,4S,5S)-2-phenylmethyl-4-(t-butyldimethyl)siloxy-5-(t-butoxycarbonyl)amino-6-phenyl hexanoic acid；(2S,4S,5R)-5-[N-(tert-butoxycarbonyl)amino]-4-tert-butyldimethylsilyloxy-2,5-dibenzyl pentanoic acid；5(S)-(Boc-amino)-4(S)-(tert-butyldimethylsilyloxy)-6-phenyl-2(R)-phenylmethyl-hexanoic acid；5(S)-(Boc-amino)-4(S)-(tert-butyldimethylsilyloxy)-6-phenyl-2(R)-phenylmethylhexanoic acid；5(S)-[(tert-butoxycarbonyl)amino]-4(S)-(tert-butyldimethylsiloxy)-6-phenyl-2(R)-(phenylmethyl)hexanoic acid；(2R,4S,5S)-2-benzyl-5-t-butoxycarbonylamino-4-t-butyldimethylsiloxy-6-phenylhexanoic acid；(2R,4S,5S)-2-benzyl-4-[tert-butyl(dimethyl)silyl]oxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-6-phenylhexanoic acid
• CAS: 98818-51-0
• 化学式: C₃₀H₄₅NO₅Si
• 分子量: 527.777
• InChiKey: UEVGWVOLUCPPDE-ZNZIZOMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.85
• 重原子数：
  37
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-(t-butyldimethylsilyloxy)-6-phenyl-2(R)-(phenylmethyl)hexanoic acid 在 四丁基氟化铵 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-{(2R,4S,5S)-2-苯甲基-5-[(叔-丁氧基羰基)氨基]-4-羟基-6-苯基己酰}-L-亮氨酰-L-苯丙氨酸酰胺
  参考文献：
  名称：

  Short Total Synthesis of Aspartyl Protease Inhibitors L-685,434, L-682,679 and L-685,458

  摘要：

  羟乙基二肽等效体L-685,434、L-682,679和L-685,458通过一系列步骤合成，包括与烯丙基三氯锡烷的偶联反应生成α-氨基醛，随后对相应的1,2-顺式和1,2-反式氨基醇进行硼氢化反应生成二醇，在TPAP条件下内酯化，内酯开环并与所需胺或二肽酰胺进行肽偶联反应。

  DOI：

  10.1055/s-2002-34891
• 作为产物：
  描述：

  对氨基溴苄 在 咪唑 、 lithium hydroxide 、 sodium ethanolate 作用下， 以 乙二醇二甲醚 、 乙醇 、 甲苯 为溶剂， 反应 78.0h， 生成 N-(1,1-dimethylethoxycarbonyl)-5(S)-amino-4(S)-(t-butyldimethylsilyloxy)-6-phenyl-2(R)-(phenylmethyl)hexanoic acid
  参考文献：
  名称：

  HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: An investigation into the role of the P1' side chain on structure-activity

  摘要：

  A systematic investigation was undertaken to determine the role of the P1' sidechain in a series of hydroxyethylene isostere based inhibitors of HIV-1 protease. Substitution and homologation of the benzyl P1' side chain of the Phe-Phe isostere based pseudo peptides 1 (L-682,679) and 2 (L-685,434) with various heteroalkyl groups leads to a series of extremely potent inhibitors of the enzyme. Several examples of the most potent inhibitors were very effective in an ex vivo cell based viral spread assay using human H9 T-lymphocytes and the IIIb isolate of HIV-1. Compound 19 is 120 times more potent than 1 and 16 times more potent than 2 in inhibiting the spread of infection in this assay.

  DOI：

  10.1021/jm00088a004

文献信息

• Rational Design, Synthesis, and Crystallographic Analysis of a Hydroxyethylene-Based HIV-1 Protease Inhibitor Containing a Heterocyclic P1'-P2' Amide Bond Isostere
  作者：Scott K. Thompson、Krishna H. M. Murthy、Baoguang Zhao、Evon Winborne、David W. Green、Seth M. Fisher、Renee L. DesJarlais、Thaddeus A. Jr. Tomaszek、Thomas D. Meek

  DOI：10.1021/jm00045a015

  日期：1994.9

  factor, R (= sigma parallel Fo magnitude of/Fc parallel/sigma magnitude of), of 0.194. The inhibitor is held in the enzyme by a set of hydrophobic and polar interactions. N-3 of the imidazole ring participates in a novel hydrogen-bonding interaction with the bound water molecule, demonstrating the effectiveness of the imidazole ring as an isosteric replacement for the P1'--P2' amide bond in hydroxyethylene-based

  已经完成了HIV-1蛋白酶高效抑制剂的合理设计和合成。抑制剂SB 206343基于源自MVT-101 / HIV-1蛋白酶复合物结构的模型，并包含一个4（5）-酰基咪唑环，可等位取代P1'-P2'酰胺键。 。它是一种竞争性抑制剂，在pH 6.0下的表观抑制常数为0.6 nM。已通过X射线衍射技术以2.3 A的分辨率确定了结合在HIV-1蛋白酶活性位点上的SB 206343的三维结构，并细化为晶体学差异因子R（=σ平行fo // Fc平行/ sigma值），为0.194。抑制剂通过一系列疏水和极性相互作用保持在酶中。咪唑环的N-3参与与结合的水分子的新型氢键相互作用，证明了咪唑环作为等规替代羟基乙烯基HIV-1蛋白酶中P1'-P2'酰胺键的有效性抑制剂。在咪唑环的N-1与Gly-127的羰基之间以及咪唑的酰基羰基氧与Asp-129的酰胺氮之间还存在氢键相互作用，这说明了4（5）的拟肽性质-酰
• Allyltrichlorostannane Additions to α-Amino Aldehydes: Application to the Total Synthesis of the Aspartyl Protease Inhibitors<scp>l</scp>-682,679,<scp>l</scp>-684,414,<scp>l</scp>-685,434, and<scp>l</scp>-685,458
  作者：Luiz C. Dias、Gaspar Diaz、Andrea A. Ferreira、Paulo R. Meira、Edílson Ferreira

  DOI：10.1055/s-2003-37649

  日期：——

  The hydroxyethylene dipeptide isosteres l-682,679, l-684,414, l-685,434, and l-685,458 were synthesized in a few steps by a sequence involving an allyltrichlorostannane coupling with an α-amino aldehyde, followed by hydroboration of the corresponding 1,2-syn and 1,2-anti amino alcohols to give the diols, lactonization under TPAP conditions, lactone opening, and peptide coupling with the desired amine or dipeptide amide. The present synthetic approach represents a practical entry to a large range of other dipeptide isosteres.

  羟基亚乙基二肽等排体l-682,679、l-684,414、l-685,434和l-685,458通过一系列步骤合成，包括与α-氨基醛的烯丙基三氯锡烷偶联、相应的1,2-顺式和1,2-反式氨基醇的氢硼化反应生成二醇、在TPAP条件下内酯化、内酯开环以及与所需胺或二肽酰胺的肽偶联。这种合成方法为其他大量二肽等排体的制备提供了一条实用的途径。
• Protease inhibitors that overcome drug resistance
  申请人：Tang Jordan J. N.

  公开号：US06969731B1

  公开（公告）日：2005-11-29

  HIV protease inhibitors are among the most powerful drugs in suppressing HIV in human patients. However, HIV developed resistance to all protease inhibitor drugs so far marketed or used in clinical trials. HIV generates resistance by mutating its protease. The strains of HIV containing mutant proteases less vulnerable to inhibitor drug are able to replicate better and maintain the infection. No effective principle exists for the design of resistance-proof HIV protease inhibitors (HIVPr). A new inhibitor has been developed based on a new concept for designing resistance invulnerable HIVPr inhibitors. In vitro data have shown that this inhibitor is effective against many known HIVPr mutants resistant to other HIVPr inhibitor drugs. The new concept is, therefore, generally applicable for the design of other resistance invulnerable HIVPr inhibitor drugs.

  HIV蛋白酶抑制剂是抑制人类HIV最强大的药物之一。然而，迄今为止市场上或在临床试验中使用的所有蛋白酶抑制剂药物对HIV都产生了抗药性。HIV通过突变其蛋白酶来产生抗药性。含有对抑制剂药物不太脆弱的突变蛋白酶的HIV菌株能够更好地复制并维持感染。目前尚无有效的原则用于设计抗耐药性的HIV蛋白酶抑制剂（HIVPr）。基于设计抗耐药性的HIVPr抑制剂的新概念已经开发出一种新的抑制剂。体外数据显示，这种抑制剂对许多已知对其他HIVPr抑制剂药物产生抗药性的HIVPr突变体具有有效性。因此，这种新概念通常适用于设计其他抗耐药性的HIVPr抑制剂药物。
• Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application
  作者：Bart Kesteleyn、Katie Amssoms、Wim Schepens、Geerwin Hache、Wim Verschueren、Wim Van De Vreken、Klara Rombauts、Greet Meurs、Patrick Sterkens、Bart Stoops、Lieven Baert、Nigel Austin、Jörg Wegner、Chantal Masungi、Inge Dierynck、Stina Lundgren、Daniel Jönsson、Kevin Parkes、Genadiy Kalayanov、Hans Wallberg、Åsa Rosenquist、Bertil Samuelsson、Kristof Van Emelen、Jan Willem Thuring

  DOI：10.1016/j.bmcl.2012.10.095

  日期：2013.1

  The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1–22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe–Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing

  描述了新型HIV-1蛋白酶抑制剂（PIs）（1-22）的设计和合成，这些抑制剂对HIV-1野生型和耐多种PI的HIV突变体临床分离株显示出高效力。铅优化从化合物1（一种Phe-Phe羟乙烯拟肽PI）开始，并旨在发现适用于长效（LA）注射药物应用的新PI。引入杂环6-甲氧基-3-吡啶基或6-（二甲基氨基）-3-吡啶基部分（R 3在）对位P1'苄基片段的位置在低个位数纳摩尔范围内具有抗病毒效力的化合物。各种芳香环上新陈代谢热点的卤化或烷基化导致PI对人肝微粒体的降解具有很高的稳定性，并且在大鼠中的血浆清除率较低。更换chromanolamine部分（R 1在P2）蛋白酶由cyclopentanolamine或cyclohexanolamine衍生物的结合位点提供了一系列的高清除率的PI（16 - 22与EC）50的HIV-1中的0.8-范围上野生型S 1.8 nM。效绩指标18和22制成纳米混
• Peptide Inhibitors of Aspartic Proteinases with Hydroxyethylene Isostere Replacement of Peptide Bond. II. Preparation of Pseudotetrapeptides Derived from Diastereoisomeric 5-Amino-2-benzyl-4-hydroxy-6-phenylhexanoic Acids
  作者：Jaroslav Litera、Jan Weber、Ivana Křížová、Iva Pichová、Jan Konvalinka、Martin Fusek、Milan Souček

  DOI：10.1135/cccc19980541

  日期：——

  Twelve pseudotetrapeptides, Boc-NHCH(CH₂Ph)CH(OH)CH₂CH(CH₂Ph) CO-Xaa-Phe-NH₂ 9-11, were prepared by [(benzotriazol-1-yl)oxy]tris(dimethylamino)phosphonium hexafluorophosphate-mediated couplings of diastereoisomeric O-silylated (2R or 2S,4R or 4S,5S)-2-benzyl-5-(tert-butoxycarbonyl)amino-4-hydroxy-6-phenylhexanoic acids 1 with dipeptides H-Xaa-Phe-NH₂ (Xaa = Gln, Glu(OBzl) or Ile) 3-5, followed by O-deprotection. Pseudotetrapeptides 9-11 were tested for inhibition of aspartic proteinases secreted by Candida albicans and C. tropicalis. The level of inhibition of both yeast proteinases was very low, contrasting with the nanomolar IC₅₀ values obtained for inhibition of HIV-1 proteinase.

  十二种伪四肽Boc-NHCH(CH2Ph)CH(OH)CH2CH(CH2Ph)CO-Xaa-Phe-NH2（9-11）通过[(苯并三唑-1-基氧基)三(二甲基氨基)磷酸六氟磷酸盐]介导的偶联反应制备，反应物为对映异构的O-硅烷基化(2R或2S,4R或4S,5S)-2-苄基-5-(tert-丁氧羰基)氨基-4-羟基-6-苯基己酸1与二肽H-Xaa-Phe-NH2（Xaa = 谷氨酰谷氨酸、谷氨酸(OBzl)或异亮氨酸）（3-5），然后进行O-去保护。伪四肽9-11被用于抑制由白念珠菌和热带白念珠菌分泌的天冬氨酸蛋白酶。两种酵母蛋白酶的抑制水平非常低，与抑制HIV-1蛋白酶所获得的纳摩尔IC50值形成对比。